Kemal Özyurt

Kemal Özyurt

Auto-generated profile, based on publicly available information

Kemal Özyurt

Ahi Evran University, Kırşehir, Turkey

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
KOKemal Ozyurt
Kemal Ozyurt
ECEmine Colgecen
Emine Colgecen
HBHalit Baykan
Halit Baykan
POPerihan Ozturk
Perihan Ozturk
MOMehmet Ozkose
Mehmet Ozkose
Recent published studies evaluating the long-pulsed 1064 nm Nd:YAG laser for superficial cutaneous vascular lesions have limited subjects and optimal treatment parameters have not been established. To determine the efficacy and safety of the long-pulsed 1064 nm Nd:YAG laser on superficial cutaneus vascular lesions and analyse retrospectively our experience of a 3-year period are the aims of this study. Over the 3-year period, 255 patients were treated [189 female and 66 male; median age 35 (range 7–65) years; Fitzpatrick skin types II-V]. Twenty-six patients with spider angioma, 130 with facial telangiectasia, and 99 with leg telangiectasia were treated. A long-pulsed 1064 nm Nd:YAG laser was used. A test dose was performed at the initial consultation and thereafter patients were reviewed and treated at 4-week intervals for 5 months. Of those patients who completed treatment and followup, 26/26 (100%) of spider angiomas, 125/130 (97%) of facial telangiectasia, and 80/99 (80,8%) of leg telangiectasia markedly improved or cleared. We suggest that the long pulsed Nd:YAG laser is a safe and effective treatment for common superficial cutaneous vascular lesions. However, it is not the first choise to use to treat superficial vessels on the face where depth is not the concern.

30 August 2019 in Allergy
Verified
Journal Article
Open access
PDF file
RERagıp Ertaş
Ragıp Ertaş
THTomasz Hawro
Tomasz Hawro
SASabine Altrichter
Sabine Altrichter
KÖKemal Özyurt
Kemal Özyurt
KEKemal Erol
Kemal Erol
MMMarcus Maurer
Marcus Maurer
Click on the article title to read more.

12 December 2018 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
RERagıp ERTAŞ
Ragıp ERTAŞ
KÖKemal Özyurt
Kemal Özyurt
CKCigdem Karakukcu
Cigdem Karakukcu
MAMuhammet Reşat AKKUŞ
Muhammet Reşat AKKUŞ
EÖEmin Özlü
Emin Özlü
MAMustafa Atasoy
Mustafa Atasoy
Background/aim: Spontaneous wheals and/or angioedema lasting longer than six weeks are described as chronic spontaneous urticaria (CSU). Omalizumab is used for the treatment of antihistamine-resistant CSU. The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), mean platelet volume (MPV), and platelet distribution width (PDW) are considered important indicators of inflammation and platelet activation in chronic diseases. We aimed to determine the NLR, PLR, MPV, and PDW levels in patients with CSU compared with healthy controls. We also aimed to investigate the effects of omalizumab therapy on these parameters in CSU patients. Materials and methods: This hospital-based, retrospective study included 143 patients with CSU and 132 healthy controls with a mean age of 40.0 +/- 13.17 and 42.0 +/- 16.34, respectively. Patients with equal or higher-than-baseline UAS scores at week 12 of omalizumab treatment were considered nonresponders, others were considered responders. We analyzed the neutrophils, lymphocytes, platelet counts, NLR, PLR, MPV, and PDW before, during, and after omalizumab treatment and compared the results with those of healthy controls. Results: CSU patients presented higher baseline MPV (P = 0.035) and lower baseline PDW values (P < 0.001) than healthy controls. There were statistically significant increases in the MPV (P < 0.001), MPV/platelet count (P = 0.005), and PDW (P = 0.003) and there was a statistically significant decrease in the NLR (P = 0.018) during omalizumab treatment. The percent increase of MPV was low in nonresponders (P = 0.009). Nonresponders had lower PDW values than responders (P = 0.040). Conclusion: The increase in the MPV and PDW may be due to platelet activation during omalizumab treatment. The decrease in the NLR may be regarded as an antiinflammatory effect of omalizumab. The effect of omalizumab on platelet and inflammatory markers may be used to discriminate the responders from nonresponders.

17 June 2020 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
ÖEÖmer Faruk Elmas
Ömer Faruk Elmas
ADAbdullah Demirbaş
Abdullah Demirbaş
ÖKÖmer Kutlu
Ömer Kutlu
FBFatih Bağcıer
Fatih Bağcıer
MMMahmut Sami Metin
Mahmut Sami Metin
Torello LottiTorello Lotti
Torello Lotti
Coronavirus disease (COVID‐19) is a highly contagious respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). COVID‐19 outbreak has been declared a pandemic by the World Health Organization on March 2020. The pandemic has affected the management of psoriasis not only for those who are under treatment but also for those who are about to begin a new therapy to control their disease. An increasing number of studies in the current literature have focused on the relationship between psoriasis and COVID‐19 from different perspectives. This narrative review includes searching the PubMed and Web of Science databases using the keywords “psoriasis,” “psoriatic arthritis,” “coronavirus,” “COVID‐19,” and “SARS‐CoV‐2.” The search was supplemented by manual searching of reference lists of included articles. A total of 11 relevant original investigations and 6 case studies was identified. The search was updated in May 2019. Due to the absence of randomized controlled trials, it is not likely to have a robust evidence‐based approach to psoriasis management in the era of COVID‐19. However, the current literature may provide some clues for safety considerations. Conventional immunosuppressive therapies such as methotrexate and cyclosporine, and anti‐tumor necrosis factor agents should not be preferred due to increased risk of infection, especially in high‐risk areas. The use of cyclosporine may pose additional risk due to the side effect of hypertension, which has been reported to be associated with susceptibility to severe COVID‐19. Considering that the current literature has provided no conclusive evidence that biologics increase the risk of COVID‐19, withdrawal of these agents should be reserved for patients with COVID‐19 symptoms. The treatment approach should be personalized, considering the advantages and disadvantages for each case separately.

7 May 2014 in Journal of Oral Pathology & Medicine
Verified
Journal Article
Closed access
PDF file
KOKemal Ozyurt
Kemal Ozyurt
AÇAhmet Çelik
Ahmet Çelik
MSMehmet Sayarlıoglu
Mehmet Sayarlıoglu
ECEmine Colgecen
Emine Colgecen
RIRahime Incı
Rahime Incı
GCGozde Y. Cetin
Gozde Y. Cetin

26 May 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
ÖEÖmer Faruk Elmas
Ömer Faruk Elmas
ADAbdullah Demirbaş
Abdullah Demirbaş
KÖKemal Özyurt
Kemal Özyurt
MAMustafa Atasoy
Mustafa Atasoy
UTUmit Tursen
Umit Tursen